(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy
The Use Of Valeriana Officinalis (Valerian) In Improving Sleep In Patients Who Are Undergoing Adjuvant Treatment For Cancer A Phase III Randomized, Placebo-Controlled, Double-Blind Study
Sponsor: Alliance for Clinical Trials in Oncology
Listed as NCT00075842, this PHASE3 trial focuses on Fatigue and Sleep Disorders and remains completed. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .